The survival rate for prostate cancer patients is high. Why is this study urgent and important? Why is PROMISE necessary?

There are 4 million men living with prostate cancer – PROMISE can help save and improve their lives.

Prostate cancer is the second most common cancer in the US (after skin cancer). More than 32,000 men die from it each year. Some populations are at even more risk. As men get older they are exponentially more likely to be diagnosed with the disease. African American men are 76{3db787e6fb6be26f007dce38ede2ba16a07d87db5a47f5cf22ce16d7dcca6695} more likely to develop it and are more than 2x more likely to die from it. The knowledge and insights that researchers will learn from PROMISE – i.e., from studying prostate cancer patients with germline pathogenic variants may help accelerate development of molecularly-targeted treatments and therapeutic strategies that may be used to treat patients prior to developing more advanced disease states. PROMISE can also help clinical trial matching by enabling trials to more rapidly identify eligible men even if those men constitute only 1{3db787e6fb6be26f007dce38ede2ba16a07d87db5a47f5cf22ce16d7dcca6695} or 2{3db787e6fb6be26f007dce38ede2ba16a07d87db5a47f5cf22ce16d7dcca6695} of all prostate cancer patients. Evidence shows that patients who participate in their first clinical trials are very likely to agree to participate in subsequent studies. Because PROMISE is not a therapeutic trial and does not require patients to leave their current treatment team, it can help expand the patient population willing to engage in clinical trials.